Psen2 Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Psen2 Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.
Presenilin 2 (PSEN2) mutations cause a rare form of autosomal dominant familial Alzheimer's disease with later onset and more variable penetrance than PSEN1.
- Gene: PSEN2 (Presenilin 2)
- Chromosome: 1q42.13
- Inheritance: Autosomal dominant
- Mutation Count: ~40 pathogenic mutations identified
- Prevalence: ~5-10% of familial AD cases
PSEN2 encodes Presenilin 2, a subunit of γ-secretase:
- γ-secretase complex: PSEN2 + NCT + APH-1 + PEN-2
- Proteolytic activity: Catalyzes intramembrane cleavage of APP
- Notch signaling: Essential for Notch receptor cleavage
- Cellular functions: Calcium regulation, ER stress response, autophagy
| Feature |
PSEN1 |
PSEN2 |
| Age of onset |
30-60 years |
50-80 years |
| Penetrance |
Near 100% |
~50-80% |
| Mutation count |
>200 |
~40 |
| Expression |
Ubiquitous |
Brain, pancreas, kidney |
- Location: Codon 141 (N→I)
- Effect: Increased Aβ42/Aβ40 ratio
- Age of Onset: 55-70 years
- Penetrance: ~50-60%
- Discovery: Volga German families
- Reference: Levy-Lahad et al., 1995
- Location: Codon 239 (M→V)
- Effect: Increased Aβ42 production
- Age of Onset: 50-65 years
- Reference: Berezovska et al., 1998
- Location: Codon 122 (T→P)
- Effect: Impaired γ-secretase activity
- Age of Onset: ~60 years
- Reference: Finckh et al., 2000
- Location: Codon 62 (R→H)
- Effect: Reduced penetrance
- Age of Onset: Variable
- Reference: Giraldo et al., 2013
Most PSEN2 mutations share common mechanisms:
- Aβ42/Aβ40 ratio increase: More aggregation-prone Aβ42 produced
- γ-secretase dysfunction: Altered cleavage specificity
- ER calcium dysregulation: Calcium homeostasis disruption
- Autophagy impairment: Lysosomal dysfunction
- Range: 50-85 years (mean ~65-70)
- Later than PSEN1: Typically 10-15 years later
- Variable: Even within families
- Memory impairment: Core AD symptom
- Progression: Generally slower than PSEN1
- Behavioral changes: Less prominent than PSEN1
- Extrapyramidal signs: Less common than PSEN1
- Amyloid plaques: Abundant Aβ deposition
- Neurofibrillary tangles: Tau pathology
- Vascular involvement: Some CAA
- Regional patterns: Similar to sporadic AD
¶ Penetrance and Variable Expressivity
- PSEN2 has lower penetrance than PSEN1
- Not all carriers develop AD
- Age-dependent risk: ~50% by age 80
- Age of onset: 50-85 years range
- Disease severity: Variable progression
- Clinical features: Heterogeneous presentation
- APOE status: APOE4 accelerates onset
- Environmental factors: Vascular risk
- Other genetic modifiers: Protective alleles
- Early-onset AD with family history
- Atypical presentation
- Autosomal dominant pattern
- Variants of uncertain significance: Common in PSEN2
- Incomplete penetrance: Family counseling complex
- Age-dependent risk: Cannot predict exact onset
- γ-secretase modulators: Shift toward shorter Aβ
- Aβ immunotherapy: Anti-Aβ antibodies
- Modulating Aβ42: Targeting aggregation
- PSEN2 carriers included in prevention trials
- DIAN-TU trials: Include PSEN2 families
- API: Alzheimer's Prevention Initiative
- Later onset may allow preventive intervention
- Variable penetrance complicates trial design
- Need for biomarker-based endpoints
Psen2 Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Psen2 Mutations In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Levy-Lahad E, et al. (1995). Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science.
- Ryman DC, et al. (2008). Clinical and pathological characterization of PSEN2 M239I mutation. Brain.
- Giraldo M, et al. (2013). Identification of PSEN2 mutations in early-onset Colombian families. Journal of Neurology.
- Sleegers K, et al. (2006). Familial Alzheimer's disease with PSEN2 mutations: Phenotypic characteristics. Brain.
- Boeras DI, et al. (2008). Presenilin mutation linked to AD results in loss of γ-secretase activity and Aβ42 production. Journal of Neurochemistry.